Microvast Holdings announces departure of chief financial officer
Troy Wichterman, the Chief Financial Officer of BioLife Solutions Inc. (NASDAQ:BLFS), a company with a market capitalization of $1.17 billion and an overall "GOOD" financial health rating according to InvestingPro, recently executed a stock sale as part of a pre-established trading plan. On March 3, 2025, Wichterman sold 660 shares of BioLife Solutions common stock at a price of $25.46 per share, totaling approximately $16,803. This transaction was made under a Rule 10b5-1 trading plan, which allows company insiders to set up a predetermined schedule for selling stocks to avoid potential conflicts of interest. Following the sale, Wichterman holds 120,960 shares directly. The stock, which has shown significant volatility and gained nearly 46% over the past year, currently trades above InvestingPro’s Fair Value estimate. Investors can access 6 additional ProTips and comprehensive analysis through the Pro Research Report, available exclusively to subscribers.
In other recent news, BioLife Solutions announced fourth-quarter financial results that exceeded expectations, with revenue reaching $22.7 million, surpassing the consensus forecast of $22.03 million. The company’s cell processing segment, which includes biopreservation media products, was a significant contributor, with revenue increasing 37% year-over-year to $20.3 million. BioLife Solutions reported a narrower-than-expected adjusted net loss of $0.01 per share, aligning with some forecasts but better than the anticipated $0.08 loss per share. Benchmark has maintained a Buy rating on BioLife Solutions, setting a price target of $30, highlighting confidence in the company’s growth prospects. Looking forward, BioLife Solutions has provided optimistic guidance for 2025, projecting revenue between $95.5 million and $99 million, which represents a 16-20% growth over 2024. The company also expects its cell processing revenue to grow 18-21% to $86.5-$89 million. BioLife’s biopreservation media is now embedded in 17 approved cell and gene therapies, with eight additional approvals or expansions anticipated in the next year. These developments reflect the company’s strategic focus on its high-margin core business and its growing position in the cell and gene therapy market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.